RESUMO
BACKGROUND: The effect of retinoic acid (RA) on breast cancer progression is controversial. Our objective was to obtain information about breast cancer progression, taking advantage of the ER-negative murine mammary adenocarcinoma model LM38 (LM38-LP constituted by luminal (LEP) and myoepithelial-like cells (MEP), LM38-HP mainly composed of spindle-shaped epithelial cells, and LM38-D2 containing only large myoepithelial cells), and to validate the role of the retinoic acid receptors (RARs) in each cell-type compartment. MATERIALS AND METHODS: We studied the expression and functionality of the RARs in LM38 cell lines. We analyzed cell growth and cell cycle distribution, apoptosis, the activity of proteases, motility properties, and expression of the molecules involved in these pathways. We also evaluated tumor growth and dissemination in vivo under retinoid treatment. RESULTS: LM38 cell lines expressed most retinoic receptor isotypes that were functional. However, only the bi-cellular LM38-LP cells responded to retinoids by increasing RARß2 and CRBP1 expression. The growth of LM38 cell sublines was inhibited by retinoids, first by inducing arrest in MEP cells, then apoptosis in LEP cells. Retinoids induced inhibitory effects on motility, invasiveness, and activity of proteolytic enzymes, mainly in the LM38-LP cell line. In in-vivo assays with the LM38-LP cell line, RA treatment impaired both primary tumor growth and lung metastases dissemination. CONCLUSION: These in-vivo and in-vitro results show that to achieve maximum effects of RA on tumor progression both the LEP and MEP cell compartments have to be present, suggesting that the interaction between the LEP and MEP cells is crucial to full activation of the RARs.
Assuntos
Adenocarcinoma/tratamento farmacológico , Modelos Animais de Doenças , Células Epiteliais/efeitos dos fármacos , Neoplasias Mamárias Animais/tratamento farmacológico , Receptores do Ácido Retinoico/metabolismo , Retinoides/farmacologia , Adenocarcinoma/metabolismo , Adenocarcinoma/patologia , Animais , Apoptose/efeitos dos fármacos , Western Blotting , Adesão Celular/efeitos dos fármacos , Movimento Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Células Epiteliais/metabolismo , Células Epiteliais/patologia , Feminino , Citometria de Fluxo , Imunofluorescência , Técnicas Imunoenzimáticas , Neoplasias Mamárias Animais/metabolismo , Neoplasias Mamárias Animais/patologia , Metaloproteinases da Matriz/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Mitose/efeitos dos fármacos , RNA Mensageiro/genética , Reação em Cadeia da Polimerase em Tempo Real , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transdução de Sinais/efeitos dos fármacos , Células Tumorais Cultivadas , Ativador de Plasminogênio Tipo Uroquinase/metabolismoRESUMO
Partial trisomy 4q is a rare chromosomal disease. It involves duplication of a portion (particularly the distal one) of the long arm of chromosome 4. In most cases results from a balanced translocation on one single progenitor. The "de novo" appearance is less common. Depending on the size and location of duplicated genetic material, patients may have different clinical manifestations. Associated eye pathology has been scarcely informed. We report on a novel case of a male infant with a proximal "de novo" 4q12-q22 duplication and bilateral iris, retinal and optic nerve coloboma.
Assuntos
Duplicação Cromossômica/genética , Cromossomos Humanos Par 4/genética , Coloboma/genética , Esotropia/diagnóstico , Humanos , Lactente , MasculinoRESUMO
La trisomía parcial 4q es una enfermedad cromosómica rara causada por la duplicación de una porción (comúnmente la distal) del brazo largo del cromosoma 4. En la mayoría de los casos resulta de una translocación balanceada de uno de los progenitores, siendo menos frecuente la aparición de novo. Los pacientes presentan diversas características clínicas según el tamaño y sitio específico de la región comprometida. Su asociación con patologías oculares ha sido escasamente comunicada. Presentamos el primer caso de un paciente pediátrico de sexo masculino con una duplicación parcial de novo del segmento proximal del brazo largo del cromosoma 4 (4q12-q22) y coloboma bilateral de iris, retina y nervio óptico.
Partial trisomy 4q is a rare chromosomal disease. It involves duplication of a portion (particularly the distal one) of the long arm of chromosome 4. In most cases results from a balanced translocation on one single progenitor. The "de novo" appearance is less common. Depending on the size and location of duplicated genetic material, patients may have different clinical manifestations. Associated eye pathology has been scarcely informed. We report on a novel case of a male infant with a proximal "de novo" 4q12-q22 duplication and bilateral iris, retinal and optic nerve coloboma.
Assuntos
Humanos , Lactente , Masculino , Duplicação Cromossômica/genética , /genética , Coloboma/genética , Esotropia/diagnósticoRESUMO
La trisomía parcial 4q es una enfermedad cromosómica rara causada por la duplicación de una porción (comúnmente la distal) del brazo largo del cromosoma 4. En la mayoría de los casos resulta de una translocación balanceada de uno de los progenitores, siendo menos frecuente la aparición de novo. Los pacientes presentan diversas características clínicas según el tamaño y sitio específico de la región comprometida. Su asociación con patologías oculares ha sido escasamente comunicada. Presentamos el primer caso de un paciente pediátrico de sexo masculino con una duplicación parcial de novo del segmento proximal del brazo largo del cromosoma 4 (4q12-q22) y coloboma bilateral de iris, retina y nervio óptico.(AU)
Partial trisomy 4q is a rare chromosomal disease. It involves duplication of a portion (particularly the distal one) of the long arm of chromosome 4. In most cases results from a balanced translocation on one single progenitor. The "de novo" appearance is less common. Depending on the size and location of duplicated genetic material, patients may have different clinical manifestations. Associated eye pathology has been scarcely informed. We report on a novel case of a male infant with a proximal "de novo" 4q12-q22 duplication and bilateral iris, retinal and optic nerve coloboma.(AU)
Assuntos
Humanos , Lactente , Masculino , Duplicação Cromossômica/genética , Cromossomos Humanos Par 4/genética , Coloboma/genética , Esotropia/diagnósticoRESUMO
Two new dolabellane diterpenoids (1 and 2) were isolated from a small sample of the deep water gorgonian octocoral Convexella magelhaenica collected as a nontarget by-catch by dredging (-93 m) in commercial Patagonian scallop fishing grounds in the South Atlantic. The structures of the new compounds, which are major metabolites in the extract, were established by spectroscopic techniques and chemical transformations. Both compounds were cytotoxic against a human pancreatic adenocarcinoma cell line at micromolar concentrations.
Assuntos
Antozoários/química , Diterpenos/isolamento & purificação , Adenocarcinoma/tratamento farmacológico , Animais , Oceano Atlântico , Diterpenos/química , Diterpenos/farmacologia , Humanos , Estrutura Molecular , Ressonância Magnética Nuclear Biomolecular , Neoplasias Pancreáticas/tratamento farmacológicoRESUMO
The investigation of the ethanol extract of fresh aerial parts of the Patagonian shrub Nardophyllum bryoides collected in the province of Chubut, Argentina, yielded eleven terpenoids. These include: three seco-ent-halimane diterpenoids (1-3), two ent-halimanes (4-5) and six pentacyclic oleanane and ursane triterpenoids (6-11). Four of these compounds (2, 6, 8 and 11) are hitherto unknown, while two others (1 and 4) have been previously reported but only as synthetic products. Several of these compounds showed moderate cytotoxicity against a human pancreatic adenocarcinoma cell line while compounds 4 and 5 were active at micromolar concentrations. The main component, seco-chiliolidic acid (1), could be isolated from this extract in large amounts, turning N. bryoides into a sustainable source of this bioactive compound.
